TRYP-0082 not checked

TRYP Therapeutics

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
4 active
5 in total · 3 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Participants will receive one dose of 25 mg of oral psilocybin on the first dosing day and a second dose of 25mg oral psilocybin on the second dosing day. TRP 8802 will be administered in a comfortable setting under the guidance of the same two therapists from the preparation period. Participants will have an in-person study visit following the resolution of the psychoactive effects of the…”In the company’s words, NCT06206265 on ClinicalTrials.gov
Tested for
Irritable Bowel Syndrome
Main trialPhase 2
“Participants with IBS (all subtypes) and with no exclusionary comorbid psychiatric or medical disorders will be enrolled in the study. This study will involve a randomized waitlist control design to investigate the rapid and sustained effects of TRP-8802 following two experimental sessions in which an oral dose of TRP-8802 is administered to participants with IBS. The study will include clinician and participant ratings of depression and anxiety pre- and post-drug-session, monitor and participant ratings of subjective drug effects during and after each drug session. This study comprises…”In the company’s words, NCT06206265 on ClinicalTrials.gov
Other names
Psilocybin

Other drugs for Irritable Bowel Syndrome

All 6 drugs for Irritable Bowel Syndrome

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting 1 Mar 2026 Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS)
Phase 2Completed 7 Mar 2024 Evaluation of Psilocybin (TRP-8802) in the Treatment of Binge Eating Disorder
Phase 2Authorised not given The impact of psilocybin on pain in fibromyalgia patients: a multicenter trial
Phase 2Authorised not given Regression of Atherosclerosis induced by liFe chAnging Experience with psiLocybin
Phase 2Authorised not given Psilocybin in treatment-resistant depression
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow TRYP-0082

Following is part of Solo: you see every change to TRYP-0082 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in